Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond

作者: Aman U. Buzdar , Gabriel N. Hortobagyi , Francisco J. Esteva , Vicente Valero , Lajos Pusztai

DOI: 10.1634/THEONCOLOGIST.6-2-133

关键词: Combination chemotherapyCA15-3Internal medicineDocetaxelMedicineOncologyVinorelbineBreast cancerMetastatic breast cancerEpirubicinCancer

摘要: Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and taxanes (paclitaxel, docetaxel) are considered most active agents for patients with advanced Traditionally, have been used combination cyclophosphamide 5-fluorouracil (FAC, FEC). single-agent activity similar to older chemotherapy treatments. There is great interest developing anthracycline/taxane combinations. Capecitabine indicated who progress after anthracycline taxane therapy. Vinorelbine gemcitabine cancer commonly as third- fourth-line palliative high-dose not well-defined remains experimental. Novel cytotoxic therapy strategies include development anthracycline, taxane, oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, multidrug resistance inhibitors. A better understanding biology providing novel treatment approaches. Oncogenes tumor-supressor genes emerging targets Trastuzumab, a monoclonal antibody directed against Her-2/neu protein, has shown prolong survival Other biologic therapies interfere signal transduction pathways angiogenesis. challenge next decade will be integrate these promising primary

参考文章(87)
J. S. Fisherman, J. A. O'Shaughnessy, K. H. Cowan, Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Seminars in Oncology. ,vol. 21, pp. 19- 23 ,(1994)
Michael L. Grossbard, Monoclonal Antibody-Based Therapy of Cancer ,(1998)
B Uziely, S Jeffers, R Isacson, K Kutsch, D Wei-Tsao, Z Yehoshua, E Libson, F M Muggia, A Gabizon, Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology. ,vol. 13, pp. 1777- 1785 ,(1995) , 10.1200/JCO.1995.13.7.1777
B. Norris, K.I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, J. Latreille, L. Rudinskas, W. Lofters, M. Trudeau, D. Osoba, A. Rodgers, Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 Journal of Clinical Oncology. ,vol. 18, pp. 2385- 2394 ,(2000) , 10.1200/JCO.2000.18.12.2385
M R Ranson, J Carmichael, K O'Byrne, S Stewart, D Smith, A Howell, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. Journal of Clinical Oncology. ,vol. 15, pp. 3185- 3191 ,(1997) , 10.1200/JCO.1997.15.10.3185
J Carmichael, K Possinger, P Phillip, M Beykirch, H Kerr, J Walling, A L Harris, Advanced breast cancer: a phase II trial with gemcitabine. Journal of Clinical Oncology. ,vol. 13, pp. 2731- 2736 ,(1995) , 10.1200/JCO.1995.13.11.2731
Duane B. Lakings, DRUG DEVELOPMENT TEAMS Clinical Research and Regulatory Affairs. ,vol. 18, pp. 329- 344 ,(2001) , 10.1081/CRP-100108180
R B Livingston, G K Ellis, J R Gralow, M A Williams, R White, C McGuirt, B B Adamkiewicz, C A Long, Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. Journal of Clinical Oncology. ,vol. 15, pp. 1395- 1400 ,(1997) , 10.1200/JCO.1997.15.4.1395
J.-M. Nabholtz, H. J. Senn, W. R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Journal of Clinical Oncology. ,vol. 17, pp. 1413- 1424 ,(1999) , 10.1200/JCO.1999.17.5.1413